ClinVar Miner

Submissions for variant NM_033360.4(KRAS):c.40G>A (p.Val14Ile) (rs104894365)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen RASopathy Variant Curation Expert Panel RCV000521254 SCV000616367 pathogenic Noonan syndrome 2017-04-03 reviewed by expert panel curation The c.40G>A (p.Val14Ile) variant in KRAS has been reported as a confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PS2_VeryStrong; PMID 16474405). The p.Val14Ile variant has been identified in at least 4 independent occurrences in patients with clinical features of a RASopathy (PS4_Moderate; PMID: 20949621, 19020799, 18958496, 17704260). In vitro functional studies provide some evidence that the p.Val14Ile variant may impact protein function (PS3; PMID: 20949621). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of KRAS (PM1; PMID 29493581). The variant is located in the KRAS gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Val14Ile variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2_VeryStrong, PS4_Moderate, PS3, PM1, PP2, PP3).
Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine RCV000844637 SCV000203925 pathogenic Noonan syndrome; Cardio-facio-cutaneous syndrome 2014-05-06 criteria provided, single submitter clinical testing The p.Val14Ile variant in KRAS has been reported in >10 individuals with clinica l features of Noonan syndrome or Cardio-facio-cutaneous syndrome, CFC (Ko 2008, Lo 2008, Gremer 2010, Nava 2007, Schubbert 2006, Zenker 2007, LMM data). This v ariant occurred de novo in at least 5 of these individuals. In addition, functio nal studies show this variant causes a gain-of-function (Schubbert 2006, Gremer 2010), an established pathogenic mechanism in Noonan spectrum disorders. Therefo re, this variant meets our criteria to be pathogenic for Noonan syndrome and CFC in an autosomal dominant manner based on de novo occurrences and functional stu dies.
GeneDx RCV000212499 SCV000207880 pathogenic not provided 2018-11-07 criteria provided, single submitter clinical testing The V14I variant in the KRAS gene has been reported previously in multiple unrelated individuals with Noonan syndrome (Schubbert et al., 2006; Nava et al., 2007; Zenker et al., 2007; Ko et al., 2008) and observed de novo in patients tested at GeneDx. This variant is not observed in large population cohorts (Lek et al., 2016). The V14I variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. In vitro functional studies have shown that V14I results in abnormal KRAS activity (Schubbert et al., 2006; Gremer et al., 2011). We interpret V14I as a pathogenic variant.
Invitae RCV000157945 SCV000552098 pathogenic Rasopathy 2019-11-20 criteria provided, single submitter clinical testing This sequence change replaces valine with isoleucine at codon 14 of the KRAS protein (p.Val14Ile). The valine residue is highly conserved and there is a small physicochemical difference between valine and isoleucine. This variant is present in population databases (rs104894365, ExAC 0.002%). This variant has been reported in numerous individuals with features of Noonan syndrome, several of which were described as de novo events (PMID: 16474405, 17056636, 17704260, 18958496, 19020799). ClinVar contains an entry for this variant (Variation ID: 12589). Experimental studies have shown that this missense change results in increased KRAS activity (PMID: 16474405, 20949621, 17875937, 24803665, 25359213). For these reasons, this variant has been classified as Pathogenic.
Integrated Genetics/Laboratory Corporation of America RCV000013420 SCV000699772 pathogenic Noonan syndrome 3 2016-04-04 criteria provided, single submitter clinical testing Variant summary: c.40G>A affects a conserved nucleotide, resulting in amino acid change from Val to Ile. 3/4 in-silico tools predict this variant to be damaging (SNPs&GO not captured due to low reliability index). This variant was found in 1/102298 control chromosomes at a frequency of 0.0000098, which does not exceed maximal expected frequency of a pathogenic allele (0.0000125). This variant has been reported in multiple NS patients and functional studies showed changes on the GDP/GTP exchange function (dramatic increase of variant both in its intrinsic and GEFcatalyzed nucleotide exchange) as well as impaired RAF-RBD binding ability (Gremer_HM_2011). In addition, multiple clinical laboratories and reputable databases classified this variant as pathogenic. Taken together, this variant was classified as a Pathogenic.
CeGaT Praxis fuer Humangenetik Tuebingen RCV000212499 SCV001248877 pathogenic not provided 2018-04-01 criteria provided, single submitter clinical testing
OMIM RCV000013420 SCV000033667 pathogenic Noonan syndrome 3 2006-03-01 no assertion criteria provided literature only
Laboratory of Translational Genomics, National Cancer Institute RCV000119792 SCV000154264 not provided Endometrial carcinoma no assertion provided not provided

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.